Targeting the prostate-specific membrane antigen (PSMA) with radiopharmaceuticals for imaging and/or therapy has demonstrated significant advancement in the management of prostate cancer patients. However, PSMA targeting remains unsuccessful in prostate cancers with low expression of PSMA, which account for 15% of cases. The neurotensin receptor-1 (NTS) has been highlighted as a suitable oncotarget for imaging and therapy of PSMA-negative prostate cancer lesions. Therefore, heterobivalent probes targeting both PSMA and NTS could improve the prostate cancer management. Herein, we report the development of a branched hybrid probe () designed to target PSMA and/or NTS bearing relevant pharmacophores and DOTA as the chelating agent. The new ligand was synthesized with a hybrid approach, which includes both syntheses in batch and in the solid phase. Saturation binding experiments were next performed on HT-29 and PC3-PIP cells to derive and values. On the PC3-PIP cells, [Ga]Ga- displayed good affinity towards PSMA ( = 53 ± 17 nM; = 1393 ± 29 fmol/10 cells) in the same range as the corresponding reference monomer. A lower affinity value towards NTS was depicted ( = 157 ± 71 nM; = 241 ± 42 fmol/10 cells on PC3-PIP cells; = 246 ± 1 nM; = 151 ± 44 fmol/10 cells on HT-29 cells) and, surprisingly, it was also the case for the corresponding monomer [Ga]Ga-. These results indicate that the DOTA macrocycle and the linker are critical elements to design heterobivalent probes targeting PSMA and NTS with high affinity towards NTS.